Cargando…
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial
Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy re...
Autores principales: | Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Huovinen, Riikka, Jukkola, Arja, Tanner, Minna, Ahlgren, Johan, Auvinen, Päivi, Lahdenperä, Outi, Villman, Kenneth, Nyandoto, Paul, Nilsson, Greger, Poikonen-Saksela, Paula, Kataja, Vesa, Bono, Petri, Junnila, Jouni, Lindman, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966968/ https://www.ncbi.nlm.nih.gov/pubmed/35020465 http://dx.doi.org/10.1200/JCO.21.02054 |
Ejemplares similares
-
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)
por: Joensuu, Heikki, et al.
Publicado: (2014) -
A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer
por: Poikonen-Saksela, Paula, et al.
Publicado: (2022) -
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013) -
High baseline Tie1 level predicts poor survival in metastatic breast cancer
por: Tiainen, Leena, et al.
Publicado: (2019) -
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)